185 related articles for article (PubMed ID: 7139646)
1. Phase I study of SOAz.
Nasca S; Jezekova D; Coninx P; Garbe E; Carpentier Y; Cattan A
Cancer Treat Rep; 1982 Dec; 66(12):2039-42. PubMed ID: 7139646
[TBL] [Abstract][Full Text] [Related]
2. A phase I clinical and pharmacokinetic trial of hepsulfam.
Ravdin PM; Havlin KA; Marshall MV; Brown TD; Koeller JM; Kuhn JG; Rodriguez G; Von Hoff DD
Cancer Res; 1991 Dec; 51(23 Pt 1):6268-72. PubMed ID: 1933887
[TBL] [Abstract][Full Text] [Related]
3. Clinical and clinical pharmacologic studies of aziridinylbenzoquinone.
Griffin JP; Newman RA; McCormack JJ; Krakoff IH
Cancer Treat Rep; 1982 Jun; 66(6):1321-5. PubMed ID: 7083235
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of (NPAz2)2NSOAz: 'SOAz'.
Rodenhuis S; Mulder NH; Sleijfer DT; Koops HS; van de Grampel JC
Cancer Chemother Pharmacol; 1983; 10(3):178-81. PubMed ID: 6861263
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
Nicaise C; Rozencweig M; Crespeigne N; Dodion P; Gerard B; Lambert M; Decoster G; Kenis Y
Cancer Treat Rep; 1986 May; 70(5):599-603. PubMed ID: 3708609
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
Surbone A; Ford H; Kelley JA; Ben-Baruch N; Thomas RV; Fine R; Cowan KH
Cancer Res; 1990 Feb; 50(4):1220-5. PubMed ID: 1688736
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of aziridinylbenzoquinone (AZQ) in advanced large bowel carcinoma.
Rubin J; van Hazel GA; Schutt AJ; Moertel CG; O'Connell MJ
Am J Clin Oncol; 1982 Oct; 5(5):539-40. PubMed ID: 7180832
[TBL] [Abstract][Full Text] [Related]
9. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
Woodcock TM; Schneider RJ; Young CW
Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study.
Roh JK; Rha SY; Lee CI; Lee KH; Lee JJ; Shim HJ; Lee SD; Kim WB; Yang J; Kim SH; Lee MG
Int J Clin Pharmacol Ther; 1998 Jun; 36(6):312-9. PubMed ID: 9660038
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical evaluation of AZQ in colorectal cancer.
Bedikian AY; Stroehlein JR; Karlin DA; Korinek J; Bodey GP
Am J Clin Oncol; 1982 Oct; 5(5):535-7. PubMed ID: 7180831
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical study of dihydroxyanthracenedione administered on a 5-day iv schedule.
Valdivieso M; Bedikian AY; Burgess MA; Savaraj N; Jeffers WB; Bodey GP
Cancer Treat Rep; 1981; 65(9-10):841-4. PubMed ID: 7273017
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule.
Von Hoff DD; Howser K; Gormley P; Bender RA; Glaubiger D; Levine AS; Young RC
Cancer Treat Rep; 1978 Oct; 62(10):1421-6. PubMed ID: 361222
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of diaziquone.
Frytak S; Eagan RT; Ames MM; Creagan ET; Nichols WC
Cancer Treat Rep; 1984; 68(7-8):975-8. PubMed ID: 6744349
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of dihydroxyanthracenedione.
Van Echo DA; Whitacre MY; Aisner J; Wiernik PH
Cancer Treat Rep; 1981; 65(9-10):831-4. PubMed ID: 7273015
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule.
Khayat D; Lokiec F; Bizzari JP; Weil M; Meeus L; Sellami M; Rouesse J; Banzet P; Jacquillat C
Cancer Res; 1987 Dec; 47(24 Pt 1):6782-5. PubMed ID: 3677107
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione).
Wynert WR; Harvey HA; Lipton A; Schweitzer J; White DS
Cancer Treat Rep; 1982 Jun; 66(6):1303-6. PubMed ID: 7083234
[TBL] [Abstract][Full Text] [Related]
18. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
[TBL] [Abstract][Full Text] [Related]
19. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of mitoxantrone by 24-hour continuous infusion.
Anderson KC; Garnick MB; Meshad MW; Cohen GI; Pegg WJ; Frei E; Israel M; Modest E; Canellos GP
Cancer Treat Rep; 1983 May; 67(5):435-8. PubMed ID: 6850662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]